US equities |
MU $1,065.56 ▼-2.06% NVDA $235.48 ▼-0.84% SNDK $1,638.36 ▼-3.19% PLTR $199.38 ▲+2.71% AMD $634.50 ▼-1.76% INTC $109.13 ▼-3.53% SPCX $163.46 ▼-2.47% META $720.18 ▼-0.16%
FinancialContent

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

64.27 -2.69 (-4.02%)
Delayed Quote Updated: 11:49 AM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher ↗
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's... 
Via Benzinga
News headline image
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market ↗
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market. 
Via Investor's Business Daily
News headline image
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Peering Into Vaxcyte's Recent Short Interest ↗
 
Via Benzinga
News headline image
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024 ↗
PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Appoints John Furey to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says ↗
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the... 
Via Benzinga
News headline image
Recap: Vaxcyte Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2024 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
News headline image
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Pricing of $750 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Appoints Whitney Jones as Chief People Officer
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales ↗
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),  
Via Benzinga
News headline image
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst ↗
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).  
Via Benzinga
News headline image
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Appoints Jacks Lee to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >